In Vivo Purging With Rituximab During Stem Cell Transplantation for Indolent Lymphoma

Publication
Article
OncologyONCOLOGY Vol 14 No 3
Volume 14
Issue 3

Autologous peripheral blood stem-cell (PBSC) transplantation may play an important role in the treatment of indolent lymphomas, as well as aggressive lymphomas. Concern about the contamination of the autologous graft with lymphoma

Autologous peripheral blood stem-cell (PBSC) transplantation may play an important role in the treatment of indolent lymphomas, as well as aggressive lymphomas. Concern about the contamination of the autologous graft with lymphoma remains, as contamination may shorten disease-free survival.

Rituximab (Rituxan) used during stem cell mobilization is a promising method for purging PBSCs of lymphoma in vivo. Similarly, when administered following transplantation, this antibody may serve as adjuvant immunotherapy. We are conducting trials with rituximab during PBSC transplant for non-Hodgkin’s lymphoma. (NHL). The purpose of these trials is to evaluate the safety and efficacy of in vivo purging with rituximab. Tumor contamination of the PBSC graft is being measured with lymphoma colony formation and/or polymerase chain reaction (PCR).

A total of 51 patients (32 males, 19 females) at a median age of 52 years (range, 32 to 67 years) have been accrued. Diagnoses included: follicular (23 patients), mantle cell (10 patients), small lymphocytic/chronic lymphocytic (13 patients), marginal zone (3 patients), and lymphoplasmacytic lymphomas (2 patients).

Patients received 375 mg/m² of rituximab on day 1 of mobilization, followed by cyclophosphamide (Cytoxan, Neosar), 2.5 g/m² on day 4, and either granulocyte-colony-stimulating factor (G-CSF [Neupogen]), 10 µg/kg starting on day 5, or granulocyte-macrophage colony-stimulating factor (GM-CSF [Leukine, Prokine]), 10 µg/kg on days 5 to 11, and G-CSF ,10 mg/kg starting on day 10 through the last day of apheresis, depending on the protocol.

Stem cells were collected using a high-volume apheresis procedure. The last 26 patients were CD34-selected for tumor depletion if ³ 5× 106 CD34/kg were collected. The preparative regimen consisted of either cyclophosphamide and total-body irradiation or busulfan (Myleran) and cyclophosphamide in patients who had received prior external irradiation. Following transplantation, patients received one or four doses of rituximab, depending on the protocol.In 46 of the 51 patients, stem cells were successfully mobilized (median, 10.9 × 106 CD34/kg; range, 2.24 × 106 to 59.5 × 106 CD34/ kg). Of the 46 patients, 38 required only one high-volume apheresis.

A total of 19 grafts were CD34 selected. Of the 19 grafts, 17 were lymphoma free in a clonogenic assay performed prior to CD34 selection, and 17 were lymphoma free following selection. Seven recipients of unmanipulated grafts had lymphomas that were positive for t(11;14) or t(14;18), and only one of these grafts was PCR positive. Results of PCR analysis of CD34-selected grafts are pending.Although follow-up is short, there has been little additional toxicity and only 1 death in the 35 transplanted patients.

CONCLUSION: Although these results are preliminary, it appears that rituximab may be an effective method for in vivo purging autologous grafts of indolent lymphoma.

Click here for Dr. Bruce Cheson’s commentary on this abstract.

Articles in this issue

Comparative Economic Analysis of the Treatment of Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL) in France Using CHOP, Fludarabine, or Rituximab
FHIT Gene, Smoking, and Cervical Cancer
Final Report on the Safety and Efficacy of Retreatment With Rituximab for Patients With Non-Hodgkins Lymphoma
Prospective, Randomized, Controlled Study of Zevalin Radioimmunotherapy Compared to Rituximab Immunotherapy for B-Cell, Non-Hodgkins Lymphoma: Interim Results
IOM Medical Error Estimates Questioned, But Legislation Considered
Less Toxic Therapies for Hodgkin’s Disease May Reduce Secondary Cancers
Preserving Fertility in Young Women With Ovarian Cancer Does Not Decrease Survival
Iodine-131 Tositumomab for Patients With Transformed, Low-Grade Non-Hodgkin’s Lymphoma: Overall Clinical Trial Experience
Survival Rates Significantly Worse For African-Americans With Endometrial Cancer
Rituximab Has Significant Activity in Patients With Chronic Lymphocytic Leukemia
Responders to Rituximab Show Continued Tumor Regression Over Time and a Progression-Free Survival That Correlates With Response Classification
PhRMA Criticizes FDA’s Proposed Rule on Antibiotic Approvals
Phase II Study of Rituximab in Combination With CHOP in Patients With Previously Untreated Intermediate- or High-Grade Non-Hodgkin’s Lymphoma
New Antibiotic Effective in Treating Gram-Positive Bacteremia
Reduced-Dose Zevalin Radioimmunotherapy for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma Patients With Preexisting Thrombocytopenia: Report of Interim Results of a Phase II Trial
Related Videos
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Related Content